CLDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Celldex Therapeutics Inc (CLDX) is not a strong buy for a beginner, long-term investor at this moment. The stock lacks significant positive catalysts, has weak financial performance, and no clear technical or proprietary trading signals to support immediate action. A 'hold' is recommended until stronger buy signals or catalysts emerge.
The MACD is negative and contracting, RSI is neutral at 45.09, and moving averages are converging, indicating no clear trend. Support is at 22.626, and resistance is at 24.849. The stock is trading near its pivot point of 23.738, showing limited momentum.
NULL. There is no recent news or significant insider or hedge fund activity. Analyst price target was raised slightly, but the rating remains neutral.
The company reported a 100% YoY revenue drop in Q3 2025, and while net income and EPS improved, they remain negative. Options data reflects bearish sentiment, and technical indicators do not suggest a strong upward trend.
In Q3 2025, revenue dropped to $0 (-100% YoY), net income improved to -$67.04M (+59.17% YoY), and EPS increased to -1.01 (+57.81% YoY). Gross margin remained at 100%, but overall financials show weak growth trends.
Barclays raised the price target to $24 from $21 but maintained an Equal Weight rating, reflecting a neutral stance on the stock.
